Education
About Us
Working with TipRanks
Follow Us
Durect Corp. (DRRX)
NASDAQ:DRRX
Earnings Data
Report Date
May 19, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.12Last Year’s EPS
-0.25Same Quarter Last Year
Moderate Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 26, 2025
|% Change Since: -1.23%
|Next Earnings Date:May 19, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted significant cost reductions and the promising potential of larsucosterol, despite facing challenges such as revenue declines and decreased cash reserves. The company's strategic focus on developing their lead asset and achieving a debt-free status are positive indicators for future growth.Company Guidance
During the DURECT Corporation's fourth quarter and full-year 2024 earnings call, CFO Timothy Papp detailed the company's financial results, highlighting total 2024 revenues of $2 million, a decline from $2.6 million in 2023, with fourth-quarter revenues at $0.5 million, down from $0.9 million the previous year. The decrease was attributed to lower earn-out revenue from Indivior, reduced feasibility agreement revenues, and decreased excipient sales. R&D expenses dropped significantly to $10.4 million in 2024 from $29.4 million in 2023, mainly due to the completion of the Affirm trial. SG&A expenses also decreased to $10 million from $12.7 million the previous year. The company ended 2024 with $12 million in cash and investments, down from $29.8 million at the end of 2023, sufficient to fund operations through Q3 2025. Additionally, the sale of the Allset product line was completed, and the proceeds were used to repay the company's term loan, leaving DURECT debt-free. Jim Brown, CEO, emphasized their focus on developing larsucosterol for alcohol-associated hepatitis, with Phase 3 trials expected to cost around $20 million and take approximately two years to yield top-line data.R&D Expense Reduction
R&D expenses decreased to $10.4 million in 2024 from $29.4 million in 2023, primarily due to lower clinical trial-related expenses and other external costs.
SG&A Expense Decrease
SG&A expenses were reduced to $10 million in 2024 from $12.7 million in the previous year, reflecting lower employee and consulting expenses.
Debt-Free Status Achieved
DURECT Corporation became debt-free after using proceeds from the sale of the Allset product line to repay their term loan.
Larsucosterol's Breakthrough Potential
Larsucosterol showed a nearly 60% reduction in mortality in Phase 2b trials, contributing to its FDA breakthrough therapy designation.
---
DRRX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
DRRX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 26, 2025 | $0.81 | $0.81 | 0.00% |
| Nov 13, 2024 | $1.21 | $1.12 | -7.44% |
| Aug 13, 2024 | $1.41 | $1.33 | -5.67% |
| May 13, 2024 | $1.07 | $0.92 | -14.02% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Durect Corp. (DRRX) report earnings?
Durect Corp. (DRRX) is schdueled to report earning on May 19, 2025, TBA Not Confirmed.
What is Durect Corp. (DRRX) earnings time?
Durect Corp. (DRRX) earnings time is at May 19, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is DRRX EPS forecast?
DRRX EPS forecast for the fiscal quarter 2025 (Q1) is -0.12.
---